0001209191-23-004732.txt : 20230124
0001209191-23-004732.hdr.sgml : 20230124
20230124200849
ACCESSION NUMBER: 0001209191-23-004732
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230120
FILED AS OF DATE: 20230124
DATE AS OF CHANGE: 20230124
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Evanson Jeff
CENTRAL INDEX KEY: 0001760511
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37759
FILM NUMBER: 23549459
MAIL ADDRESS:
STREET 1: C/O ONCOBIOLOGICS, INC.
STREET 2: 7 CLARKE DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Outlook Therapeutics, Inc.
CENTRAL INDEX KEY: 0001649989
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 383982704
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0930
BUSINESS ADDRESS:
STREET 1: 485 ROUTE 1 SOUTH
STREET 2: BUILDING F, SUITE 320
CITY: ISELIN
STATE: NJ
ZIP: 08830
BUSINESS PHONE: 6096193990
MAIL ADDRESS:
STREET 1: 485 ROUTE 1 SOUTH
STREET 2: BUILDING F, SUITE 320
CITY: ISELIN
STATE: NJ
ZIP: 08830
FORMER COMPANY:
FORMER CONFORMED NAME: Oncobiologics, Inc.
DATE OF NAME CHANGE: 20150804
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-01-20
0
0001649989
Outlook Therapeutics, Inc.
OTLK
0001760511
Evanson Jeff
C/O OUTLOOK THERAPEUTICS, INC.
485 ROUTE 1 SOUTH, BLDG F, SUITE 320
ISELIN
NJ
08830
0
1
0
0
Chief Commercial Officer
Common Stock
2023-01-20
4
S
0
267000
1.11
D
745975
D
These shares were sold to cover taxes upon lapse of Issuer's repurchase right as to 75% of the shares as provided in that certain Consulting Agreement dated January 27, 2020.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.10 - $1.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
/s/ Lawrence Kenyon, Attorney-in-Fact
2023-01-24